Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
    X

    Find Oncology Drugs in Phase II Clinical Development in SPAIN

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              PharmaMar

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SPAIN Spain

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EYEFORPHARMA

              Participation Not Confirmed

              Update your events

              PharmaMar, Jazz Pharma Announce FDA Acceptance and Priority Review of NDA for Lurbinectedin in Relapsed Small Cell Lung Cancer

              Contact the Supplier

              Lead Product(s): Lurbinectedin

              Therapeutic Area: Oncology

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 17, 2020

              Details:

              PharmaMar submitted the NDA to FDA in December 2019 based on data from the Phase II monotherapy basket trial, which included evaluation of lurbinectedin for the treatment of relapsed SCLC.

              PharmaMar

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SPAIN Spain

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EYEFORPHARMA

              Participation Not Confirmed

              Update your events

              PharmaMar announces the initiation of a study of lurbinectedin in combination with immunotherapy

              Contact the Supplier

              Lead Product(s): Lurbinectedin,Atezolizumab

              Therapeutic Area: Oncology

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 14, 2020

              Details:

              This is a Phase I-II study to determine the recommended dose andnefficacy of lurbinectedin in combination with atezolizumab (Roche)nin patients with advanced Small Cell Lung Cancer.

              PharmaCompass__DigitalAd